Related references
Note: Only part of the references are listed.Interleukin-28B Polymorphism Improves Viral Kinetics and Is the Strongest Pretreatment Predictor of Sustained Virologic Response in Genotype 1 Hepatitis C Virus
Alexander J. Thompson et al.
GASTROENTEROLOGY (2010)
Resistance to Direct Antiviral Agents in Patients With Hepatitis C Virus Infection
Christoph Sarrazin et al.
GASTROENTEROLOGY (2010)
EARLY ON-TREATMENT RESPONSES DURING PEGYLATED IFN PLUS RIBAVIRIN ARE INCREASED FOLLOWING 13 DAYS OF COMBINATION NUCLEOSIDE POLYMERASE (RG7128) AND PROTEASE (RG7227) INHIBITOR THERAPY (INFORM-1)
E. Gane et al.
JOURNAL OF HEPATOLOGY (2010)
ACTIVITY OF TELAPREVIR ALONE OR IN COMBINATION WITH PEGINTERFERON ALFA-2A AND RIBAVIRIN IN TREATMENT-NAIVE GENOTYPE 2 AND 3 HEPATITIS-C PATIENTS: FINAL RESULTS OF STUDY C209
G. R. Foster et al.
JOURNAL OF HEPATOLOGY (2010)
Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance
Dongliang Ge et al.
NATURE (2009)
Genetic variation in IL28B and spontaneous clearance of hepatitis C virus
David L. Thomas et al.
NATURE (2009)
Genome-wide association of IL28B with response to pegylated interferon-α and ribavirin therapy for chronic hepatitis C
Yasuhito Tanaka et al.
NATURE GENETICS (2009)